Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generics Review Data From US FDA Reveals Positives, Negatives For Industry

Nov 05 2023

• By Derrick Gingery

generic drugs — FY 2023 generic drug data includes mixed messages for sponsors. • Source: Shutterstock

Related Content

US FDA’s New Generics Chief: We Need More Flexibility For Complex Products

Aug 28 2023

New Workload Categories Add To FDA Staff Needs, Help Increase User Fees

Aug 21 2023

PDUFA Fees Push Higher In FY 2024, While Biosimilar Fees Race Downward

Jul 27 2023

FDA Contradicts AAM's Generic Market Consolidation Argument

Nov 21 2017

Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says

Jan 04 2018

US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals

Sep 17 2018

US FDA's Generics Program Reaches 'Steady State' Milestone

Sep 07 2018

US FDA Generic Approvals Break 900 Barrier In FY 2019

Oct 17 2019

Additional Topics

United States Generic Drugs Review Pathway Regulation User Fees BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window